Avalyn Pharma (NASDAQ:AVLN) Upgraded to “Hold” at Wall Street Zen

Avalyn Pharma (NASDAQ:AVLN) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

AVLN has been the subject of a number of other research reports. Morgan Stanley boosted their price target on Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Thursday, August 13th. Weiss Ratings restated a “sell (d+)” rating on shares of Avalyn Pharma in a research note on Wednesday. Finally, Raymond James Financial assumed coverage on Avalyn Pharma in a report on Friday, October 2nd. They issued an “outperform” rating and a $60.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Avalyn Pharma currently has a consensus rating of “Moderate Buy” and an average price target of $60.00.

Avalyn Pharma Trading Down 1.0%

Shares of AVLN opened at $30.28 on Friday. Avalyn Pharma has a fifty-two week low of $22.24 and a fifty-two week high of $40.17. The company has a fifty day moving average of $28.66. The company has a current ratio of 33.12, a quick ratio of 33.12 and a debt-to-equity ratio of 0.04.

Avalyn Pharma (NASDAQ:AVLN) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.03). As a group, equities analysts forecast that Avalyn Pharma will post -3.86 EPS for the current fiscal year.

Insider Buying and Selling

In other Avalyn Pharma news, insider Fmr Llc sold 175,000 shares of the firm’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $29.07, for a total value of $5,087,250.00. Following the transaction, the insider directly owned 2,109,535 shares of the company’s stock, valued at $61,324,182.45. This trade represents a 7.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Hedge Funds Weigh In On Avalyn Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of AVLN. China Universal Asset Management Co. Ltd. purchased a new position in Avalyn Pharma in the 3rd quarter worth approximately $29,000. Manchester Capital Management LLC acquired a new position in shares of Avalyn Pharma during the third quarter worth $36,000. Profund Advisors LLC purchased a new position in shares of Avalyn Pharma in the third quarter valued at $668,000. Bank of New York Mellon Corp acquired a new stake in Avalyn Pharma during the 2nd quarter valued at $1,321,000. Finally, State Street Corp acquired a new stake in Avalyn Pharma during the 2nd quarter valued at $10,501,000.

Avalyn Pharma Company Profile

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company’s pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn’s inhaled candidates are being studied as potential alternatives to oral treatment.